{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:54:46Z","timestamp":1793825686664,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ccm.2020.05.006","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T18:12:23Z","timestamp":1597255943000},"page":"475-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease"],"prefix":"10.1016","volume":"41","author":[{"given":"Takudzwa","family":"Mkorombindo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Dransfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib1","doi-asserted-by":"crossref","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ccm.2020.05.006_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00062614","article-title":"Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis","volume":"44","author":"Bafadhel","year":"2014","journal-title":"Eur Respir J"},{"issue":"3 Pt 2","key":"10.1016\/j.ccm.2020.05.006_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1164\/ajrccm.157.3.157315","article-title":"Efficacy and safety of inhaled corticosteroids. New developments","volume":"157","author":"Barnes","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/15412555.2010.510160","article-title":"Mortality in COPD: causes, risk factors, and prevention","volume":"7","author":"Berry","year":"2010","journal-title":"COPD"},{"key":"10.1016\/j.ccm.2020.05.006_bib8","first-page":"1","article-title":"Inflammatory mechanisms in the lung","volume":"2","author":"Moldoveanu","year":"2009","journal-title":"J\u00a0Inflamm Res"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.ccm.2020.05.006_bib10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1056\/NEJMc1715454","article-title":"Mepolizumab for eosinophilic COPD","volume":"378","author":"Xia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccm.2020.05.006_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/09031936.93.02100935","article-title":"A\u00a0trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis","volume":"2","author":"Engel","year":"1989","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/thx.46.5.372","article-title":"Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease","volume":"46","author":"Auffarth","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2020.05.006_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0007-0971(88)90038-1","article-title":"The use of high dose inhaled beclomethasone dipropionate as a means of assessing steroid responsiveness in obstructive airways disease","volume":"82","author":"Wardman","year":"1988","journal-title":"Br J Dis Chest"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1164\/ajrccm\/146.2.389","article-title":"Aerosolized beclomethasone in chronic bronchitis: improved pulmonary function and diminished airway inflammation","volume":"146","author":"Thompson","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"9105","key":"10.1016\/j.ccm.2020.05.006_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(97)03471-5","article-title":"Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease","volume":"351","author":"Paggiaro","year":"1998","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ccm.2020.05.006_bib16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2020.05.006_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib18","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur Respir J"},{"issue":"7245","key":"10.1016\/j.ccm.2020.05.006_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","article-title":"Blood eosinophils as a marker of response to inhaled corticosteroids in COPD","volume":"47","author":"Barnes","year":"2016","journal-title":"Eur Respir J"},{"issue":"10030","key":"10.1016\/j.ccm.2020.05.006_bib21","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"9356","key":"10.1016\/j.ccm.2020.05.006_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ccm.2020.05.006_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 \u03bcg) or salmeterol (50 \u03bcg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2020.05.006_bib28","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/COPD.S136527","article-title":"Fluticasone propionate\/formoterol for COPD management: a randomized controlled trial","volume":"12","author":"Papi","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","article-title":"Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study","volume":"106","author":"Sharafkhaneh","year":"2012","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ccm.2020.05.006_bib32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01219-2018","article-title":"Inhaled corticosteroids in COPD: friend or foe?","volume":"52","author":"Agusti","year":"2018","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.ccm.2020.05.006_bib34","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/resp.13422","article-title":"Double combination inhalers in COPD: how to get your head around this data","volume":"23","author":"Singh","year":"2018","journal-title":"Respirology"},{"issue":"18","key":"10.1016\/j.ccm.2020.05.006_bib35","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2020.05.006_bib36","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMe068307","article-title":"Treating COPD--the TORCH trial, P values, and the Dodo","volume":"356","author":"Rabe","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2020.05.006_bib37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"Cardiovascular events in patients with COPD: TORCH study results","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"issue":"19","key":"10.1016\/j.ccm.2020.05.006_bib38","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/heartjnl-2016-310897","article-title":"Cardiovascular outcomes with an inhaled beta2-agonist\/corticosteroid in patients with COPD at high cardiovascular risk","volume":"103","author":"Brook","year":"2017","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1164\/rccm.201610-2086OC","article-title":"Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk","volume":"197","author":"Calverley","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.ccm.2020.05.006_bib40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201607-1421OC","article-title":"Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction","volume":"195","author":"Martinez","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2020.05.006_bib43","series-title":"A15. ICS IN COPD: the pendulum keeps swinging","first-page":"A1015","article-title":"Reduction in all-cause mortality with single inhaler triple therapy (FF\/UMEC\/VI) versus dual therapy (FF\/VI and UMEC\/VI) in symptomatic patients with COPD: prespecified analysis of the Phase III IMPACT Trial","author":"Lipson","year":"2018"},{"issue":"10048","key":"10.1016\/j.ccm.2020.05.006_bib44","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"10082","key":"10.1016\/j.ccm.2020.05.006_bib45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"issue":"10125","key":"10.1016\/j.ccm.2020.05.006_bib46","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib47","doi-asserted-by":"crossref","first-page":"1801230","DOI":"10.1183\/13993003.01230-2018","article-title":"Inhaled corticosteroid containing combinations and mortality in COPD","volume":"52","author":"Vestbo","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.006_bib48","article-title":"Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies","volume":"52","author":"Fabbri","year":"2018","journal-title":"Eur Respiratory Soc"},{"key":"10.1016\/j.ccm.2020.05.006_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0954-6111(97)90102-5","article-title":"Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety","volume":"91","author":"Derendorf","year":"1997","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib50","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1183\/09031936.00095807","article-title":"New evidence of risk factors for community-acquired pneumonia: a population-based study","volume":"31","author":"Almirall","year":"2008","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0091-6749(96)80217-X","article-title":"Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids","volume":"97","author":"Johnson","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.ccm.2020.05.006_bib52","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.1997.03540330044033","article-title":"Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma","volume":"277","author":"Garbe","year":"1997","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1081-1206(10)61870-4","article-title":"Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone","volume":"90","author":"Fukushima","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9343(02)01143-9","article-title":"The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials","volume":"113","author":"Alsaeedi","year":"2002","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.ccm.2020.05.006_bib55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/thoraxjnl-2012-202872","article-title":"Inhaled corticosteroids in COPD and the risk of serious pneumonia","volume":"68","author":"Suissa","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ccm.2020.05.006_bib56","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0012-3692(15)31287-3","article-title":"Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II","volume":"126","author":"Tashkin","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1183\/09031936.06.00131905","article-title":"COPD is associated with increased mortality in patients with community-acquired pneumonia","volume":"28","author":"Restrepo","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.006_bib58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/COPD.S121389","article-title":"Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records","volume":"12","author":"Williams","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ccm.2020.05.006_bib60","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.201908-1550OC","article-title":"Inhaled steroids, circulating eosinophils, chronic airway infection and pneumonia risk in chronic obstructive pulmonary disease: a network analysis","volume":"201","author":"Martinez-Garcia","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib61","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","author":"Kew","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1164\/rccm.201409-1654PP","article-title":"Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?","volume":"191","author":"Festic","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib64","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","article-title":"Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis","volume":"68","author":"Andrejak","year":"2013","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib65","doi-asserted-by":"crossref","first-page":"1700037","DOI":"10.1183\/13993003.00037-2017","article-title":"The risk of mycobacterial infections associated with inhaled corticosteroid use","volume":"50","author":"Brode","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0002-9343(02)01297-4","article-title":"The risk of osteoporosis in Caucasian men and women with obstructive airways disease","volume":"114","author":"Sin","year":"2003","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.ccm.2020.05.006_bib67","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1164\/rccm.200310-1349OC","article-title":"Loss of bone density with inhaled triamcinolone in Lung Health Study II","volume":"170","author":"Scanlon","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib68","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1183\/09031936.02.00276602","article-title":"Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler\u00ae","volume":"19","author":"Johnell","year":"2002","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2020.05.006_bib69","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1378\/chest.08-3016","article-title":"Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study","volume":"136","author":"Ferguson","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2020.05.006_bib70","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ccm.2020.05.006_bib71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/thx.2011.160028","article-title":"Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies","volume":"66","author":"Loke","year":"2011","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.ccm.2020.05.006_bib72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","article-title":"Inhaled corticosteroids and the risks of diabetes onset and progression","volume":"123","author":"Suissa","year":"2010","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.ccm.2020.05.006_bib73","doi-asserted-by":"crossref","first-page":"e0162903","DOI":"10.1371\/journal.pone.0162903","article-title":"Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study","volume":"11","author":"Price","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib74","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.amjmed.2008.09.048","article-title":"The association of inhaled corticosteroid use with serum glucose concentration in a large cohort","volume":"122","author":"Slatore","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.ccm.2020.05.006_bib75","first-page":"19","article-title":"Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial","volume":"173","author":"Drescher","year":"2015","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.ccm.2020.05.006_bib76","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1002\/jps.24089","article-title":"Impact of study design on the evaluation of inhaled and intranasal corticosteroids' effect on hypothalamic\u2013pituitary\u2013adrenal Axis function","volume":"103","author":"Fan","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib77","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaip.2018.01.025","article-title":"Inhaled corticosteroids safety and adverse effects in patients with asthma","volume":"6","author":"Heffler","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"9240","key":"10.1016\/j.ccm.2020.05.006_bib78","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib79","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","article-title":"Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","article-title":"Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial","volume":"186","author":"Bafadhel","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2020.05.006_bib81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccm.2020.05.006_bib82","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2020.05.006_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ccm.2020.05.006_bib84","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"14","key":"10.1016\/j.ccm.2020.05.006_bib85","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2020.05.006_bib86","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2020.05.006_bib87","doi-asserted-by":"crossref","first-page":"1600839","DOI":"10.1183\/13993003.00839-2016","article-title":"Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids","volume":"49","author":"Kunz","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2020.05.006_bib88","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/COPD.S125616","article-title":"\u201cReal-life\u201d inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD","volume":"12","author":"Vogelmeier","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.ccm.2020.05.006_bib89","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study","volume":"166","author":"van der Valk","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2020.05.006_bib90","series-title":"C41. Long acting bronchodilator therapy in COPD II","first-page":"A5483","article-title":"Effect of treatment withdrawal on outcomes in the Summit study","author":"Vestbo","year":"2017"},{"issue":"3","key":"10.1016\/j.ccm.2020.05.006_bib91","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-term triple therapy de-escalation to indacaterol\/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523120300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523120300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:58:42Z","timestamp":1759453122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523120300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0272523120300320"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2020.05.006","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2020.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}